Prediabetes pp 347-355 | Cite as

Effects of Immunosuppression with Cyclosporine on Beta Cell Function and Clinical Remission in Very Early Overt Type I Diabetes

  • J. Dupre
  • C. R. Stiller
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 246)


The hypothesis that insulin-dependent diabetes mellitus (IDDM) in man results from destruction of the pancreatic beta cells by an autoimmune process was prompted by circumstantial evidence. The association of IDDM with markers of the major histocompatibility complex suggests that genetic factors are important in determining susceptibility to the disease, and indicates possible involvement of the immune system. Antibody-mediated and cell-mediated immunological phenomena are demonstrable in high-risk subjects in the pre-clinical phase, and in patients with early overt disease. The histology of the Islets of Langerhans was consistent with an inflammatory immune attack. The hypothesis was strengthened by recognition that IDDM can occur in animals as the result of an autoimmune attack on the pancreatic beta cells, and that the process in animals can be prevented by immunomodulatory interventions. On this background, and with growing experience of the use of immunosuppressive drugs in organ transplantation, clinical trials of immunotherapy early in the course of overt IDDM have been undertaken. This summary deals with the now substantial experience with Cyclosporine as the immunosuppressive agent.


Beta Cell Clinical Remission Trough Level Autoimmune Attack Calculated Creatinine Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Marner, B., Agner, T., Binder, C., Lernmark, A., Nerup, J., Mandrup-Oulsen, T., Walldorf, S., 1985, Increased reduction in fasting C- peptide is associated with islet cell antibodies in Type I (insulin-dependent) diabetic patients. Diabetologia 28: 875–880.PubMedCrossRefGoogle Scholar
  2. 2.
    Drash, A.L., 1987, In: Clinical Care of the Diabetic Child, Year Book Medical Publications Inc., Chicago: 33–51.Google Scholar
  3. 3.
    Srikanta, S., Ganda, O.P., Eisenbarth, G.S., Soeldner, J.S., 1983, Islet-cell antibodies and beta-cell function in monozygotic triplets and twins initially discordant for Type I diabetes mellitus. N Engl J Med 308: 322–325.PubMedCrossRefGoogle Scholar
  4. 4.
    Dupre, J., Stiller, C.R., Gent, M., Donner, A., Graffenried, B., Murphy, G., Heinrichs, D., Jenner, M.R., Keown, P.A., Laupacis, A., Mahon, J., Martell, R., Rodger, N.W., and Wolfe, B.M., 1988, Effects of Immunosuppression with Cyclosporine in Insulin-Dependent Diabetes Mellitus of Recent Onset: The Canadian Open Study at 44 months. Transplantation Proceedings. Vol. XX, No. 3, Suppl. 4: 184–192.Google Scholar
  5. 5.
    Ruiz, P., Kolbech, P.C., Scroggs, M.W., Sanfilippo, F., 1988, Associations between Cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantaion, 45: 91–95.CrossRefGoogle Scholar
  6. 6.
    Dupre, J., Stiller, C.R., Gent, M., von Graffenried, B., Momah, C.I., Jenner, M., Wolfe, B.M., Mahon, J., Atkinson, P., 1988, Shortterm Methylprednisolone combined with nephrotoxic doses of cyclosporine induces high rates of remission in Type I diabetes. Proceedings International Confereence, Immunointervention in Autoimmune Diseases.Google Scholar
  7. 7.
    Assan, R., 1988, The Use of Cyclosporine in Adult Type I Diabetes. Proceedings International Conference, ImmunoIntervention in Autoimmune Diseases.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • J. Dupre
    • 1
  • C. R. Stiller
    • 1
  1. 1.University of Western OntarioLondonCanada

Personalised recommendations